Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Robotic-Assisted Surgery: Taking MIS By Storm

Executive Summary

Robotically assisted surgical devices are one of the hottest and fastest growing segments in the market for minimally invasive surgery (MIS) products, with a global market opportunity projected to reach more than $10 billion by 2021. A growing number of competitors hope to capture share and further expand the market by targeting key procedures and geographies with next generation robotic surgery systems and robotic-like technologies designed to improve outcomes and enable more complex procedures to be performed via an MIS approach.

Advertisement

Related Content

How Israel's Digital Innovators Are Capturing The Minds Of Medtronic And Others
Device Debuts: Medtronic, Boston Scientific, Philips, Seventh Sense, Vortex, 410 Medical
J&J Device Chief Gary Pruden Retiring; Sandra Peterson Will Take On Duties
Earnings Winners And Losers: ABT, ISRG, STJ, SYK
Zimmer Biomet Mirrors Medtronic's Robotics Move With Medtech SA

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT036019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel